Section C — Coach Sleep — Clinical Sleep Medicine and Circadian Translation
This section covers the Master's chapter on Clinical Sleep Medicine and Circadian Translation, Lessons 1 through 5: Clinical Sleep Medicine at Practice Depth, Circadian Translational Medicine, Sleep Pharmacology and Hypnotic Landscape, CBT-I and Behavioral Sleep Medicine, and Consumer Sleep Technology and the Wellness-Industry-Research Gap. All material is already in the chapter — no new content.
Part A — Vocabulary (20 points, 2 points each)
Select the single best answer for each question.
1. Spielman 1986 3P (predisposing-precipitating-perpetuating) behavioral model of insomnia (foundational anchor):
A) Was a pharmacology paper B) Established the conceptual framework for behavioral sleep medicine that anchored four decades of CBT-I development; predisposing factors (genetic, personality) plus precipitating events (stressors, medical) plus perpetuating factors (conditioned arousal, dysfunctional sleep behaviors) explain chronicity; foundational for cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment C) Was a drug trial D) Has been superseded
2. AASM is:
A) An animal model B) American Academy of Sleep Medicine — the principal professional society for U.S. sleep medicine producing clinical practice parameters, board certification framework, and the International Classification of Sleep Disorders (ICSD-3-TR is current) C) A research consortium D) A drug
3. Eckert OSA phenotyping framework (2013 AJRCCM):
A) Was a single physiology B) Four physiological traits — passive upper airway collapsibility (Pcrit), loop gain, arousal threshold, muscle responsiveness — driving variable OSA pathophysiology and supporting individualized treatment beyond universal CPAP first-line C) Was an obsolete framework D) Applied only to pediatric
4. Hypoglossal nerve stimulation (cross-reference Breath Master's L2):
A) Is a sleep position B) An implantable device (Inspire Medical, Strollo 2014 NEJM STAR trial) stimulating the hypoglossal nerve to activate genioglossus during inspiration — alternative for selected CPAP-intolerant OSA patients with anatomic and PSG criteria; one outcome of Eckert phenotyping framework (poor muscle responsiveness phenotype) C) Is a behavioral intervention D) Has been superseded
5. SERVE-HF trial (Cowie 2015 NEJM):
A) Was a positive trial B) Cautionary trial of adaptive servo-ventilation for central sleep apnea in heart failure with reduced ejection fraction — primary outcome neutral, increased cardiovascular mortality in treatment arm; led to ASV contraindication in HFrEF central sleep apnea; foundational sleep-cardiology safety case C) Was a drug trial D) Has been superseded
6. DSWPD is:
A) A respiratory disorder B) Delayed sleep-wake phase disorder — circadian rhythm sleep-wake disorder with chronic delay of sleep onset and wake time relative to socially desired timing; AASM circadian classification; diagnostic via sleep history, sleep diary, often actigraphy; clinical management with chronotherapy, light therapy at appropriate phase, melatonin at appropriate phase C) A pharmacologic class D) Has been superseded
7. DORAs are:
A) Antidepressants B) Dual orexin receptor antagonists — newer hypnotic class (suvorexant, lemborexant, daridorexant) acting at OX1R and OX2R; alternative to benzodiazepine receptor agonists; different addiction and tolerance profile; FDA approvals 2014-2022 C) Antipsychotics D) Anti-seizure medications
8. Benzodiazepine-opioid co-prescribing risk (cross-reference Brain Master's L1, Breath Master's L5):
A) Is minimal B) FDA 2016 boxed warnings, Sun 2017 BMJ documentation of concurrent BZ-opioid use and overdose mortality; the synergistic respiratory depression mechanism — opioid MOR effect on preBötC plus BZ GABA-A allosteric modulation reducing arousal-to-hypercapnia threshold — makes co-prescribing a major iatrogenic mortality surface C) Has been resolved D) Applies only to elderly
9. MCTQ is:
A) A respiratory test B) Munich Chronotype Questionnaire — Roenneberg validated chronotype assessment based on sleep timing on work-free days; standard research and clinical chronotype measurement; foundational for social-jet-lag epidemiology C) A drug class D) An imaging modality
10. Consumer sleep tracker overclaim at Master's depth:
A) Has no methodological concern B) Operates at the wellness-industry-research-gap pattern — wrist-worn accelerometry and PPG-based devices estimate sleep stages with substantial measurement error versus PSG (with sleep-stage agreement often <70-80% versus PSG reference); marketing claims often exceed validated capability; clinical decision-making should not rely on consumer device sleep-stage data C) Is fully validated D) Has been resolved
Part B — Concept Comprehension (20 points, 2 points each)
Select the single best answer for each question.
11. CBT-I clinical efficacy and AASM first-line positioning:
A) Is unsupported B) CBT-I (cognitive behavioral therapy for insomnia) — including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, relaxation — is positioned as first-line treatment for chronic insomnia by AASM clinical practice parameter; effect sizes comparable to or exceeding pharmacotherapy with durable benefit; access limited by trained-clinician availability with digital CBT-I (Sleepio, dCBT-I) expanding access C) Has been superseded by pharmacotherapy D) Applies only to acute insomnia
12. Chronopharmacology framework at Master's depth:
A) Has no clinical application B) The discipline of timing pharmacologic interventions to circadian phase for efficacy and tolerability — chemotherapy timing in oncology, BP medication timing including the MAPEC/Hygia studies (later contrasted with TIME 2022 Lancet finding null timing effect), corticosteroid timing in inflammatory conditions; emerging clinical translational application of circadian biology C) Is purely theoretical D) Has been resolved
13. Khalsa 2003 PRC paper:
A) Was a behavioral study B) Established phase-response curve (PRC) for bright light in humans — light pulses produce phase delays in evening and phase advances in early morning; foundational for clinical chronotherapy with light timing (CRSWD treatment, jet lag, shift work) C) Was a drug trial D) Has been superseded
14. Shift work disorder at Master's clinical depth:
A) Has no clinical recognition B) AASM circadian classification disorder — chronic difficulty sleeping during desired sleep time and excessive sleepiness during desired wake time, associated with shift work schedule; clinical management includes shift scheduling considerations, strategic light exposure/restriction, sleep hygiene, melatonin at appropriate phase, alertness-promoting medication in selected cases (modafinil approval); intersects IARC Group 2A shift work classification cross-reference Light Master's L4 C) Has been resolved D) Applies only to nurses
15. Sleep neurology emergency: REM sleep behavior disorder (RBD):
A) Is a benign variant B) Loss of normal REM atonia with dream-enactment behaviors — frequently a prodromal phase of alpha-synucleinopathy (Parkinson disease, dementia with Lewy bodies, multiple system atrophy); ~80-90% conversion to clinical synucleinopathy over decade-plus follow-up in idiopathic RBD cohorts; major clinical translational research area for early disease detection C) Is unrelated to neurodegeneration D) Has been superseded
16. Z-drugs (zolpidem, eszopiclone, zaleplon) at Master's pharmacology depth:
A) Are entirely different from benzodiazepines B) Non-benzodiazepine hypnotics with selective GABA-A α1-subunit affinity producing hypnotic effect with somewhat different side-effect profile than classic BZs; substantial parasomnia risk (sleep-driving, sleep-eating with zolpidem); FDA 2013 zolpidem dose reduction in women due to morning impairment; not free of dependence/tolerance concerns C) Are free of side effects D) Are antidepressants
17. Saper-Scammell-Lu 2005 sleep-wake flip-flop framework:
A) Was a behavioral paper B) Updated the flip-flop sleep-wake switch framework — VLPO mutual inhibition with ascending arousal nuclei, orexin stabilization, narcolepsy as orexin-loss flip-flop instability; foundational neural circuit framework for sleep-wake regulation; Bachelor's-tier Sleep anchor returning at Master's depth as substrate for clinical pharmacology mechanism understanding C) Applied only to invertebrates D) Has been superseded
18. Borbély 1982 two-process model at Master's depth:
A) Has no clinical application B) Process S (homeostatic sleep pressure, building during wakefulness) plus Process C (circadian drive, oscillating ~24-hour) jointly determine sleep timing and propensity; foundational theoretical framework that informs clinical sleep medicine including CBT-I sleep restriction (manipulating Process S), light therapy (Process C), and the integrated sleep timing assessment C) Has been superseded D) Applies only to research
19. Sleep apnea and cardiovascular outcome trials at Master's depth:
A) Have demonstrated universal CPAP cardiovascular benefit B) SAVE trial (McEvoy 2016 NEJM) — CPAP in OSA with cardiovascular disease did not reduce composite cardiovascular events versus usual care; the disconnect between observational OSA-CV-risk literature and intervention RCT outcomes is one of the standard cautionary cases in clinical sleep medicine; informs careful framing of CPAP indication beyond symptom relief C) Have been superseded D) Apply only to severe OSA
20. Coach Sleep integrator position at Master's depth (Consolidation):
A) Is abstract B) The Consolidation position at Master's translational depth holds clinical sleep medicine practice (Sleep L1), circadian medicine and chronotherapy clinical translation (Sleep L2), sleep pharmacology and hypnotic landscape (Sleep L3), CBT-I and behavioral sleep medicine (Sleep L4), and consumer sleep tracker overclaim (Sleep L5) — the temporal restoration mechanism now framed through its clinical and public-health translational layers C) Same as Synchronizer D) Same as Substrate
Part C — Application (30 points, 6 points each)
Write 5-7 complete sentences with specific reference to chapter content, primary literature citations, and methodological framings where asked.
21. Spielman 1986 3P model and CBT-I as first-line treatment. Walk the Spielman 3P (predisposing-precipitating-perpetuating) behavioral model of insomnia and its role as foundational anchor of the Master's chapter. Identify CBT-I components (sleep restriction, stimulus control, cognitive restructuring) and the AASM first-line positioning. Discuss access limitations (trained clinician availability) and the digital CBT-I (dCBT-I) expansion via platforms including Sleepio. Position the chapter's foundational anchor alongside Appel 1997 (Food), Zarate 2006 (Brain), Morris 1953 (Move), Nielsen 2013 (Cold), Casa 2007 (Hot), ARDSNet 2000 (Breath), Lam 2016 (Light), and Heerspink 2020 (Water).
22. Eckert phenotyping framework cross-coach integration with Breath Master's L2. Walk the Eckert 2013 AJRCCM four-physiological-trait OSA phenotyping framework — passive upper airway collapsibility (Pcrit), loop gain, arousal threshold, muscle responsiveness. Identify individualized treatment options beyond universal CPAP first-line: oral appliances/surgical for anatomic-predominant, oxygen/acetazolamide for high loop gain, selective arousal threshold elevation, hypoglossal nerve stimulation for poor muscle responsiveness (Strollo 2014 NEJM STAR trial). Cross-reference Breath Master's Lesson 2 (sleep-disordered breathing clinical management) — how do the Sleep and Breath chapters jointly hold sleep-disordered breathing at Master's translational depth?
23. Circadian medicine chronopharmacology and the MAPEC/Hygia vs TIME 2022 contrast. Walk the chronopharmacology framework at Master's translational depth — the MAPEC and Hygia studies suggesting evening BP medication timing produced better cardiovascular outcomes than morning timing in Spanish cohorts. Then walk the TIME 2022 Lancet large pragmatic randomized trial showing null effect of morning versus evening BP medication timing on cardiovascular outcomes. Explain the methodological tensions (pragmatic versus efficacy trial design, population differences, outcome ascertainment). What does the contrast demonstrate about chronopharmacology as a Master's-level translational research frontier?
24. BZ-opioid co-prescribing risk cross-coach integration with Brain L1 and Breath L5. Walk the synergistic respiratory depression mechanism — opioid MOR effect on preBötC inspiratory neurons plus BZ GABA-A allosteric modulation reducing arousal-to-hypercapnia threshold. Cite FDA 2016 boxed warnings and Sun 2017 BMJ documentation. Cross-reference Brain Master's Lesson 1 (substance use disorder treatment landscape) and Breath Master's Lesson 5 (opioid respiratory depression + naloxone distribution). Why is the BZ-opioid co-prescribing pattern a major iatrogenic mortality surface and how do the three chapters integrate to address it at Master's translational depth?
25. Wellness-industry-research-gap pattern in consumer sleep tracking. Apply the wellness-industry-research-gap pattern (operating across Cold L3 cold-and-mental-health, Hot L4 sauna-claim hierarchy, Move L5 exercise-as-supplement, Light L5 circadian-lighting overclaim, Breath L3 breathwork-as-treatment, Water L3 functional-water claims) to consumer sleep tracker overclaim at Master's depth. State the measurement-error documentation against PSG reference for wrist-worn accelerometry and PPG-based devices. Apply the five-point framework (design, population, measurement, effect size, replication) to a hypothetical consumer device claim of "improved sleep-stage detection." How does graduate-level sleep research literacy inform clinical conversations with patients citing consumer device data?
Continue to Section D — Coach Move.